Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:17:21 EDT Sat 05 Oct 2024
Enter Symbol
or Name
USA
CA



Z:JNJ - JOHNSON & JOHNSON - http://www.jnj.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JNJ - Z0.1159.68·160.500.2160.29-0.22-0.15,331.6846,28564,520159.63  160.50  158.775168.85  143.1319:59:0616:3015 min RT 2¢

Recent Trades - Last 10 of 64520
Time ETExPriceChangeVolume
19:59:06Z160.2805-0.219512
19:57:15Z160.29-0.212
19:56:38Z160.930.4350
19:54:05Z160.29-0.2110
19:40:57Z160.29-0.211
19:32:28Z160.29-0.212
19:32:19Z160.2885-0.211513
19:30:51Z160.29-0.216
19:19:45Z160.29-0.2175
19:19:28Z160.29-0.2115

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-04 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
2024-10-02 09:00U:JNJNews ReleaseERLEADA(TM) (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
2024-09-30 16:05U:JNJNews ReleaseJohnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO(TM)-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-30 08:05U:JNJNews ReleaseJohnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
2024-09-27 16:30U:JNJNews ReleaseCARVYKTI(TM) is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
2024-09-27 13:05U:JNJNews ReleaseDARZALEX(TM) (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
2024-09-27 13:00U:JNJNews ReleaseDARZALEX FASPRO(TM)-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-27 08:05U:JNJNews ReleaseNovel combination of TALVEY(TM) (talquetamab-tgvs) and TECVAYLI(TM) (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary
2024-09-27 08:00U:JNJNews ReleaseTALVEY(TM) (talquetamab-tgvs) and DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
2024-09-20 15:43U:JNJNews ReleaseJohnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
2024-09-19 18:54U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
2024-09-16 02:50U:JNJNews ReleaseNeoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
2024-09-15 02:30U:JNJNews ReleaseNew data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
2024-09-14 09:45U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
2024-09-14 03:10U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
2024-09-11 18:22U:JNJNews ReleaseTREMFYA(TM) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
2024-09-10 17:15U:JNJNews ReleaseDexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT(TM) (amivantamab-vmjw)
2024-09-08 13:47U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
2024-09-05 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2024-08-29 08:00U:JNJNews ReleaseJohnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis